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Abstract
 
Statins, known as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase, exhibit numerous functions related to inflammation, such as MHC class II down-regula-
tion, interference with T cell adhesion, and induction of apoptosis. Here we demonstrate that
both subcutaneous and oral administration of atorvastatin inhibit the development of actively
induced chronic experimental autoimmune encephalomyelitis in SJL/J mice and significantly
reduce the inflammatory infiltration into the central nervous system (CNS). When treatment
was started after disease onset, atorvastatin reduced the incidence of relapses and protected from
the development of further disability. Both the reduced autoreactive T cell response measured
by proliferation toward the encephalitogenic peptide PLP139–151 and the cytokine profile in-
dicate a potent blockade of T helper cell type 1 immune response. In in vitro assays atorvastatin
not only inhibited antigen-specific responses, but also decreased T cell proliferation mediated
by direct TCR engagement independently of MHC class II and LFA-1. Inhibition of prolifer-
ation was not due to apoptosis induction, but linked to a negative regulation on cell cycle pro-
gression. However, early T cell activation was unaffected, as reflected by unaltered calcium
fluxes. Thus, our results provide evidence for a beneficial role of statins in the treatment of au-
toimmune attack on the CNS.
Key words: EAE • multiple sclerosis • HMG-CoA reductase • T cell • autoimmunity
 
Introduction
 
Several large-scale intervention trials have demonstrated
that statin treatment reduces the risk of myocardial infarc-
tion and stroke (1). This effect was so far explained by their
impact on the lipid profile through the inhibition of an
enzyme crucial to cellular cholesterol synthesis, 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA)
 
*
 
 reductase.
However, increasing clinical and experimental evidence
suggests that the pharmacological effects of statins relate not
only to cholesterol lowering but also to anti-inflammatory
effects on the immune system. Two independent studies
have shown that both pravastatin and lovastatin reduce se-
rum concentrations of C-reactive protein, a marker of in-
flammation, by 
 

 
15% (2, 3). In addition, clinical trials on
transplant rejections indicate the therapeutic potential of
statins as immunosuppressive agents. For example, pravas-
tatin improves survival and lowers the incidence of acute
rejection after heart transplantation (4). Concerning the
underlying mechanisms, Kwak et al. demonstrated in an
initial report that statins inhibit the IFN-
 

 
–induced expres-
sion of MHC class II on most APCs, including B cells and
macrophages (5). A recent paper showed that certain statins
inhibit the LFA-1–dependent stimulation of T cells and
that a lovastatin-based LFA-1 inhibitor reduces infiltration
of neutrophils in the murine thioglycollate-induced perito-
nitis model (6). Members of the statin family were found to
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*
 
Abbreviations used in this paper: 
 
BP, birch pollen; CDK, cyclin-depen-
dent kinase; CNS, central nervous system; EAE, encephalomyelitis;
HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; ICAM-1, inter-
cellular adhesion molecule-1; MBP, myelin basic protein; MS, multiple
sclerosis; PLP, proteolipid protein; TCL, T cell line. 
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interfere with the LFA-1–intercellular adhesion molecule
(ICAM)-1 interaction by binding to a novel regulatory site
of integrins in a HMG-CoA–independent manner. These
observations raise the question as to whether statin therapy
may also be beneficial in other chronic inflammatory con-
ditions and immune diseases (7).
In this report, we used the pharmacologically active sta-
tin atorvastatin to dissect the role of statins in brain inflam-
mation and to explore their therapeutic potential for au-
toimmunity. Therefore, we applied atorvastatin in murine
experimental autoimmune encephalomyelitis (EAE; refer-
ence 8), a well-characterized CD4
 

 
 T cell–mediated ani-
mal disease model of multiple sclerosis (MS; references 9,
10). As for its human counterpart, induction of EAE in
susceptible strains of rodents leads to central nervous
system (CNS) inflammation, demyelination, and axonal
pathology (11). We demonstrate that the signs of relaps-
ing–remitting EAE in SJL/J mice can be diminished by
atorvastatin in vivo both in a preventive and therapeutic
fashion. CNS inflammation associated with EAE was sig-
nificantly reduced. Our data indicate that this therapeutic
effect is caused by a down-regulation of Th1 immune re-
sponse, as confirmed by the reduction of autoreactive T
cell response and infiltration into the CNS. We further
demonstrate an HMG-CoA-reductase–dependent inter-
ference of atorvastatin with the cell cycle in human anti-
gen–specific T cells.
 
Materials and Methods
 
Treatment with Atorvastatin and Mevalonate. 
 
Because pure
atorvastatin (Pfizer) is not soluble in PBS, the stock was dis-
solved in 2% DMSO before subcutaneous administration at a
daily dose of 20 or 200 
 

 
g per mouse (corresponding to 1 or 10
mg/kg body weight) and in methylcellulose 0.5% (Sigma-
Aldrich) before oral administration of 200 
 

 
g per mouse (10
mg/kg) for the in vivo experiments. Accordingly, the in vitro
investigations were performed at a concentration of 1, 5, and
25 
 

 
M of atorvastatin (100 
 

 
M stock in 2% DMSO). In all as-
says of our work, the carrier was used as vehicle control in the
same dilution as atorvastatin. To test the reversibility of the ator-
vastatin effect, 
 
l
 
-mevalonate was used at a concentration of 200
 

 
M. Therefore, 
 
l
 
-mevalonic acid lactone (Sigma-Aldrich) was
activated by 1 N NaOH. The resulting solution was neutralized
with 1 N HCl to pH 7.2, diluted with distilled water, and steril-
ized by filtration thereafter.
 
Induction, Treatment, and Clinical Evaluation of Active EAE.
 
Female SJL/J mice (6–8 wk; 
 

 
20 g body weight; Charles River
Laboratories) were immunized subcutaneously with 75 
 

 
g pro-
teolipid protein (PLP) 139–151 (purity 
 

 
95%; Pepceuticals) in
0.2 ml emulsion consisting of equal volumes of PBS and CFA
(Difco) and containing 6 mg/ml of mycobacterium tuberculosis
H37Ra (Difco). 200 ng pertussis toxin (List Biological Labora-
tories) was administered intraperitoneally at days 0 and 2 (12).
Mice were scored for EAE as follows: 0, no disease; 1, tail weak-
ness; 2, paraparesis; 3, paraplegia; 4, paraplegia with forelimb
weakness or paralysis; and 5, moribund or dead animals (13).
Mean clinical scores at separate days and mean maximal scores
were calculated by adding scores of individual mice and dividing
by number of mice in each group. All procedures were con-
 
ducted according to protocols approved by the local animal wel-
fare committee.
 
Neuropathology. 
 
Mice killed with narcotics were transcar-
dially perfused with 4% paraformaldehyde. Spinal cords and brain
stems were removed, postfixed in 4% paraformaldehyde, and em-
bedded in paraffin. Vibratome sections (Shandon) were stained
with hematoxylin and eosin for visualization of inflammatory in-
filtrates and evaluated in a blinded manner for the amount of in-
flammation as described previously (14).
 
Human and Murine Antigen-specific T Cells.
 
Human CD4
 

 
 T
cell lines (TCLs) specific for human myelin basic protein
(MBP; MA14) or birch pollen (BP; MB7, MB8, EG8) were es-
tablished with a modified “split-well” protocol (15) and have
been characterized previously (16). All antigen-specific TCLs
had at least three restimulations before the assay and a stimula-
tion index 
 

 
3. Establishment of the PLP139–151-specific
mouse TCL Je1 was performed as described previously (17).
For murine bulk cell cultures, spleen and draining lymph node
cells were dissociated with a cell strainer (Sigma-Aldrich) and
cultured in 96- (for proliferation assays) or 24-well microtiter
plates (for cytokine assays).
 
Proliferation and Cytokine Assays. 
 
For the proliferation of hu-
man TCLs, 0.7 
 

 
 10
 
5
 
 cells were stimulated with 2 
 

 
 10
 
5
 
 autol-
ogous-irradiated (3,000 rad) PBMC as antigen-presenting cells
and the corresponding antigen, or with anti-CD3 (OKT3;
coated at 1 
 

 
g/ml; American Type Culture Collection) and 1
 

 
g/ml anti-CD28 (R&D Systems). For the proliferation of the
mouse PLP139–151-specific TCL Je1, 0.7 
 

 
 10
 
5
 
 cells were
stimulated with 1.4 
 

 
 10
 
5
 
 autologous-irradiated (3,000 rad)
splenocytes as APC and 5 
 

 
g/ml peptide. For proliferation as-
says, [
 
3
 
H]Thymidine (0.5 
 

 
Ci per well; Amersham Biosciences)
incorporation was measured 72 h after stimulation with antigen
and 48 h with anti-CD3/CD28, radioactivity as counts per min-
utes detected by a MicroBeta
 
®
 
 
 

 
 counter (PerkinElmer) after
18 h. For the ex vivo proliferation and cytokine measurement, 2 
 

 
10
 
6
 
 splenocytes were stimulated with different peptide concen-
trations. Human IFN-
 

 
 and mouse IL-2, IL-12, IFN-
 

 
, IL-4,
and IL-10 were measured in supernatants from cell cultures (2 
 

 
10
 
6
 
/ml in 24-well plates; incubation time 48 h for IL-2, IL-12,
and IFN-
 

 
; 96 h for IL-4 and IL-10) with commercially avail-
able sandwich ELISA
 
®
 
 kits (mouse, BD Biosciences; human,
R&D Systems).
 
Western Blot. 
 
Immunoblot studies were performed as de-
scribed previously (16). In brief, after 2-h blocking, membranes
were incubated for 1 h with specific primary antibodies: 2 
 

 
g/ml
monoclonal mouse anti-p27
 
Kip1
 
 (Santa Cruz Biotechnology,
Inc.), 1 
 

 
g/ml polyclonal rabbit anti-CDK4 (Santa Cruz Biotech-
nology, Inc.), and 24 ng/ml monoclonal anti–
 

 
-actin. Mem-
branes were incubated for 1 h with 1.25 
 

 
g/ml secondary anti-
body coupled to horseradish peroxidase (DakoCytomation).
Specific bands were detected with the ECL-Plus™ System (Am-
ersham Biosciences). CDK4 and p27
 
Kip1
 
 immunoblots were se-
quentially incubated with anti–
 

 
-actin as control.
 
Measurements of Intracellular Calcium [Ca
 
2
 

 
]
 
i
 
. 
 
Intracellular
free calcium concentrations [Ca
 
2
 

 
]
 
i
 
 were measured in human
TCLs using flow cytometry (18). Cells, 5 
 

 
 10
 
6
 
/ml, were
loaded with 5 
 

 
M Indo-1-AM (Molecular Probes) for 30 min at
37
 

 
C. Unloaded dye was removed by centrifugation, and cells
were resuspended in calcium-free PBS. The analyses were per-
formed on a flow-activated cell sorter (BD FACS
 
®
 
 LSR; Bec-
ton Dickinson). The FL4 (510/20) and FL5 (380LP) fluores-
cence channels were used to measure free Indo-1 and the
complex Ca
 
2
 

 
–Indo-1 concentrations, respectively. Calculation
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of the ratio of these two fluorescent wavelengths allows the
evaluation of changes in cytosolic-free Ca
 
2
 

 
 concentrations
[Ca
 
2
 

 
]
 
i
 
 independently of the cell size and the intracellular
Indo-1 concentration. The flow rate was set to 300 events/s and
the mean ratio of 2,000 cells were noted every 20 s. 5 
 

 
M Tg
(Calbiochem) was added after 80 s to fully deplete intracellular
Ca
 
2
 

 
 stores and therefore activate calcium release-activated cal-
cium channels (CRACs). After a 5-min incubation with Tg, 1.2
mM calcium was added to the cell suspension to monitor the
extent of Ca
 
2
 

 
 influx.
 
Apoptosis Assay. 
 
DNA fragmentation of apoptosis-suscepti-
ble Jurkat T cells was determined as described previously (15).
2 
 

 
 10
 
5
 
 cells were incubated with atorvastatin or vehicle at the
indicated concentrations. As a positive control, CD95-mediated
apoptosis was induced by a soluble murine CD95 ligand. After
24 h, cells were washed and incubated overnight at 4
 

 
C in a hy-
potonic fluorochrome solution containing 50 
 

 
g/ml propidium
iodide before flow cytometry for quantitative detection of hy-
podiploid DNA.
 
Statistics. 
 
For group comparisons (mean maximal disease scores
and number of inflammatory foci in spinal cord), the Student’s 
 
t
 
 test
was applied. To compare the EAE courses, statistical analysis of re-
peated measurements was performed by analysis of variance using
the Fisher’s pairwise least significant difference test with Bonferroni
adjustment (19). The incidence of relapses (defined as the acquisi-
tion of a clinical score 
 

 
1 for at least two consecutive days; modi-
fied according to reference 20) was compared using the 
 
	
 
2
 
 test.
 
Results and Discussion
 
Atorvastatin Ameliorates Disease Severity in EAE. 
 
To ex-
plore the efficacy of statins on actively induced EAE,
 
PLP139–151-immunized SJL/J mice were treated subcuta-
neously with 200 
 

 
g per mouse (corresponding to 10 mg/
kg body weight) atorvastatin (all treatments using pure
substance) from day 1 after immunization. This dosage was
chosen in accordance with previous work on statin effects
in murine lipid metabolism (21–23) and stroke models (24,
25), assuming that mouse and man greatly differ in their
statin metabolism (26–29). Preventive treatment attenu-
ated the first disease attack and reduced clinical symptoms
(Fig. 1 A), resulting in a reduced mean maximum disease
score of 2.4 
 


 
 0.3 (mean 
 


 
 SEM) in the atorvastatin
group versus 3.4 
 


 
 0.3 in the vehicle group (data from
two independent experiments; 
 
n
 
 
 

 
 12 for both groups;
P 
 

 
 0.05). Continued atorvastatin therapy of these animals
significantly protected them from the development of
long-term neurological sequelae, as the mean clinical
scores between groups were statistically different (F
 
14–70
 
 [1,
57] 
 

 
 4.4, P 
 

 
 0.05). This marked prophylactic effect of
atorvastatin led us to investigate its therapeutic potential to
suppress established disease. Hence, we delayed starting
treatment with atorvastatin until animals developed the
first symptoms. Treatment with atorvastatin prevented
mice from disease exacerbation with a relapse rate of
37.5% (three out of eight) in the atorvastatin group com-
pared with 87.5% (seven out of eight) in the vehicle group
(
 
	
 
2
 
 
 

 
 4.3; P 
 

 
 0.05). Neurological disability during re-
lapse was reduced (Fig. 1 B) with a maximum disease score
of 1.2 
 


 
 0.4 in the atorvastatin group versus 2.4 
 


 
 0.4 in
the vehicle group (P 
 

 
 0.05), and significantly lower mean
Figure 1. Atorvastatin sup-
presses the clinical severity of
EAE in a preventive and thera-
peutic manner. (A) For the pre-
ventive treatment paradigm, 200
g atorvastatin (n  12; shaded
circles) or vehicle alone (n  12;
open circles) were injected sub-
cutaneously daily from the day of
immunization onward. Both the
maximum disease scores and the
mean clinical disease scores were
significantly reduced in the ator-
vastatin group. (B) For the non-
preventive therapy, mice were
randomized into two groups
(n  8 for both groups) after the
establishment of disease at day 10
and subsequently treated. Signifi-
cant differences were noted for
the maximum disease scores, the
relapse incidence, and the mean
disease scores for the time of the
relapse. (C) Mice were treated
subcutaneously with 20 g ator-
vastatin (n  10 for atorvastatin
group, n  7 for vehicle group).
(D) For oral therapy, mice were
treated with 200 g (n  7 for
both groups). For all trials, treatment periods are indicated by horizontal hatched bars. The treatment effect was statistically significant as outlined in the
marked range for all presented EAE courses (*, P  0.05, analysis of variance).
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clinical disease scores (F35–50 [1, 15]  4.7; P  0.05). The
lower dose of 20 g per mouse atorvastatin was less effec-
tive (F18–20 [1, 3]  5.1; P  0.05; Fig. 1 C). Treatment
with orally administered atorvastatin (200 g per mouse)
exhibited a beneficial effect in the same model (F25–28
[1, 4]  4.8; P  0.05; Fig. 1 D). Our observations pro-
vide evidence that the HMG-CoA-reductase inhibitor
atorvastatin has marked therapeutic effects on chronic re-
lapsing-remitting autoimmune encephalomyelitis in SJL/J
mice. Clinical disease in atorvastatin-treated mice was con-
siderably milder compared with vehicle-treated controls, as
displayed by reduced maximal disease severity and favor-
able long-term outcome. Moreover, therapy with ator-
vastatin was beneficial even when started after disease
manifestation, indicating a role for therapy of an already
established autoimmune disorder.
Histological examination of mice killed directly after the
maximum of the relapse revealed large inflammatory le-
sions scattered throughout the brain stem and spinal cord in
vehicle-treated mice, whereas those treated with the statin
revealed significantly less inflammation (Fig. 2). Thus, in
line with the clinical scores, we found that atorvastatin
treatment resulted in reduced CNS inflammation. Taking
the reported almost pleiotropic effects of the statins into ac-
count, possible explanations for these data are either a de-
crease in peripheral immune response or reduced transmi-
gration into the CNS. Therefore, we addressed the
mechanisms underlying the atorvastatin-mediated blockade
of neuroinflammation.
Atorvastatin Treatment Inhibits T Cell Response in EAE.
First, we examined the T cell response resulting from statin
treatment in EAE, which was investigated after 10 d of
treatment in cells from spleens exposed to the encephalito-
genic PLP139–151 epitope. As shown in Fig. 3 A, mice
treated with atorvastatin revealed a lower proliferative
response after antigenic challenge, compared with vehicle-
treated animals. In line with previous reports (25), treat-
ment of normocholesterolemic SJL/J mice with atorvasta-
tin for 10 d in contrast to therapy over several months did
not alter serum cholesterol levels, with 57.3 
 2.9 versus
55.7 
 1.2 mg/dl in atorvastatin- versus vehicle-treated
mice, respectively (mean 
 SEM).
Inhibition of the Th1 Response by Atorvastatin in EAE.
Assessment of the cytokine pattern in response to PLP re-
stimulation indicated that atorvastatin treatment led to a
reduction of IL-2 and IL-12 as well as IFN- secretion, as
demonstrated for splenocyte cultures (Fig. 3, B–D). Inter-
estingly, although immune cells from atorvastatin-treated
animals showed a diminished proliferative response to-
ward PLP, the levels of IL-4 and IL-10 in the supernatants
of splenocytes were even higher on atorvastatin treatment,
as compared with vehicle-treated animals (Fig. 3, E and
F). IL-12 drives the T cell differentiation toward the Th1,
and IFN- is a proinflammatory cytokine, possibly in-
volved in the initiation of exacerbations in relapsing-
remitting MS (30). In EAE, IFN- directs trafficking of
leukocytes into the CNS by orchestrating chemokine pro-
duction (31), and its overproduction is usually associated
with relapses (32). Thus, inhibition of proliferation, IL-12,
and IFN- production points to an antiinflammatory ac-
tivity of atorvastatin, which accounts for the reduction of
clinical disease. Our results demonstrate that atorvastatin is
an effective immunomodulatory agent for the treatment of
murine EAE by suppressing disease-causing Th1 response
while enhancing regulatory cytokines. Clinical trials may
clarify whether the same effects can be achieved in MS pa-
tients.
Decreased Proliferation of Murine and Human Lymphocytes
Associated with Interference in Cell Cycle Regulation. In view
of the reduced proliferative response in atorvastatin-treated
animals, we investigated whether this statin interferes with
the antigen-specific proliferation of a murine CD4+ Th1
PLP-specific TCL Je1 in vitro. As shown in Fig. 4 A, ator-
vastatin blocked the antigen-response in a dose-dependent
manner. The doses of 1–25 µM atorvastatin used in these
assays are comparable to the levels measured in human
plasma (29, 33). Having demonstrated the inhibitory effects
of atorvastatin on murine cells in vivo and in vitro, we next
studied the proliferation of human antigen-specific CD4
TCLs. As indicated in Fig. 4 B, antigen-specific prolifera-
tion of the human TCL MB8 was suppressed by atorvasta-
tin in a dose-dependent manner.
Interestingly, the blockade of proliferation was also ob-
served when atorvastatin was added to proliferating T
cells, 24 or 48 h after stimulation (Fig. 5 A). This points to
further pathways of immunomodulatory statin function in
addition to those involving a reduced MHC class II up-
regulation by inhibition of the inducible promoter IV of
the transactivator CIITA (5), and the blockade of LFA-1–
Figure 2. Decreased inflammation in spinal cords of atorvastatin-
treated mice. Representative histology of spinal cord longitudinal sections
was obtained from the EAE course presented in Fig. 1 A. Inflammatory
infiltration was visualized by hematoxylin and eosin staining. (A) Vehicle-
treated animals showed typical perivascular infiltrates (arrowheads) com-
prised of lymphocytes and macrophages. (B) In contrast, atorvastatin-
treated animals showed a markedly reduced inflammatory reaction.
Average number of inflammatory foci/ocular field 
 SEM in spinal cords
of atorvastatin- and vehicle-treated mice as detected in hematoxylin and
eosin–stained sections (P  0.01, Student’s t test).
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Schmidt et al. (6), is not sufficient to explain the antipro-
liferative effect of atorvastatin in our CD3/CD28-stimu-
lated T cells.
Reversibility of Atorvastatin-induced Interference with T Cell
Proliferation and IFN- Secretion by L-Mevalonate. Because
atorvastatin may confer its immunomodulatory effects,
both dependent on (5) and independent of (6) inhibition of
HMG-CoA reductase, it was important to clarify whether
the direct T cell–targeted antiproliferative effect reported
here is mediated by the HMG-CoA reductase pathway. In-
deed, both proliferation (Fig. 5 B) and IFN- secretion
(Fig. 5 C) in human antigen–specific T cells could be re-
versed by l-mevalonate providing direct evidence that the
immunomodulatory effects of atorvastatin are mediated by
inhibition of HMG-CoA reductase.
Impact of Atorvastatin on Cell Cycle Regulation. Because
statins block the synthesis of isoprenoid intermediates and
subsequently inhibit the function of intracellular signaling
ICAM-1 interactions (6). To confirm this hypothesis, we
tested the ability of atorvastatin to block T cell prolifera-
tion in response to direct T cell receptor engagement in-
dependent of antigen presentation. As shown in Fig. 5 B,
[3H]Thymidine uptake of the antigen-specific TCL MB7
stimulated with anti-CD3/CD28 was markedly sup-
pressed by atorvastatin. Thus, in an environment lacking
APC, expressing MHC class II and ICAM-1, atorvastatin
is nonetheless capable of inhibiting proliferation. Costim-
ulation via T cell–mounted LFA-1 needs the addition of
ICAM-1 not expressed on the T cell itself because direct
T cell stimulation via CD3–TCR pathway alone does not
induce phosphatidylinositol 3-kinase activation, a reliable
indicator of costimulation mediated through ICAM-1
into the T cell (34). Therefore, a down-regulation of
LFA-1 expression resulting in attenuated transmigration of
mononuclear cells into the CNS (35), as well as ligation to
the novel LFA-1 binding site as demonstrated by Weitz-
Figure 3. Atorvastatin treatment in vivo suppresses the PLP-specific priming response. Three mice per group were treated with either atorvastatin (200
µg per mouse) or vehicle from day 1 after immunization with PLP as described in Materials and Methods. (A) Proliferation of splenocytes in response to
PLP (at the indicated concentrations) was assessed in quadruplicate cultures and expressed as stimulation index (mean 
 SEM; atorvastatin, shaded bars;
vehicle, open bars). (B) Accordingly, IL-2 was determined in the supernatants. Whereas IL-12 (C) as well as IFN- (D) were found at lower concentra-
tions in the atorvastatin-treated mice than in those vehicle-treated, levels of IL-4 (E) and IL-10 (F) were higher in supernatants from splenocytes after
treatment with atorvastatin. Data are presented as mean 
 SEM; differences between atorvastatin and vehicle treatment are significant (P  0.05; Stu-
dent’s t test).
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molecules (36), next we tested whether the observed anti-
proliferative effect of atorvastatin is caused by interference
at the cell cycle level. We did not find an impact of atorva-
statin on early T cell activation, because calcium influx
was unaffected (Fig. 5 D). However, we could observe
that growth inhibition by atorvastatin was associated with
a down-regulation of the cyclin-dependent kinase 4
(CDK4; Fig. 5 E). Investigating the expression of p27kip1, a
CDK inhibitor involved in negative regulation of the T
cell cycle, we found an up-regulation on atorvastatin incu-
bation, which could be reversed by l-mevalonate (Fig. 5
F). This finding, together with a persisting effect of atorva-
statin, even when added late in culture (Fig. 5 A), suggests
an inhibition of cell cycle progression at the late part of the
G1 phase.
No Induction of Apoptosis in T Cells by Atorvastatin. Princi-
pally, atorvastatin may not only inhibit but also directly
eliminate cells by induction of apoptotic mechanisms
(37). Testing statin-incubated T cells with the trypan
blue exclusion assay, we had no indication of increased
cell death. To exclude an apoptosis-inducing capacity of
atorvastatin in T cells, which might be responsible for the
antiproliferative effect, we measured DNA fragmenta-
tion. However, atorvastatin did not induce relevant DNA
fragmentation, even in apoptosis-susceptible Jurkat T
cells, compared with both untreated and vehicle-treated
cells (Fig. 5 G), thus ruling out a proapoptotic role for
this substance.
Disease pathogenesis in EAE induced by PLP139–151
in SJL/J mice is regarded as a prototypical T cell–mediated
autoimmune disorder. As in MS, it involves the activation
and expansion of autoreactive T cells, migration through
the blood–brain barrier, restimulation by antigen chal-
lenge within the CNS, and induction of local inflamma-
tion, leading to demyelination and axonal damage. The
reduced amount of inflammatory infiltration in the CNS
from statin-treated mice might reflect the inhibition of T
cell entry into the CNS. This hypothesis is supported by
the fact that certain statins were capable of inhibiting
thioglycollate-induced neutrophil migration (6). How-
ever, our data on the suppression of Th1 immune re-
sponse outside the brain and the lack of the statin-binding
site in the integrin very late antigen-4 (6), which is impor-
tant for the transmigration through the blood–brain bar-
rier, argue against a prominent impact of statins on T cell
migration into the CNS. Thus, the reduced amount of in-
flammation in the CNS of statin-treated animals in our
work most likely results from an effect on the peripheral
immune response. In fact, in line with Youssef et al.
(38), we found a diminished proliferative response of
CD4 lymphocytes toward the encephalitogenic peptide
PLP139–151, accompanied by reduced production of Th1
cytokines and a relative increase in the regulatory cyto-
kines IL-4 and IL-10. It is striking that even the addition
of the statin at a late stage of T cell activation resulted in a
marked decrease of proliferation. This finding indicates
that the immunomodulatory effects of atorvastatin are
comprised of other mechanisms in addition to down-reg-
ulation of MHC class II expression and inhibition of LFA-
1–ICAM-1 interaction. 
Investigations in the murine system indicate that statins
exert pleiotropic immunomodulatory effects on both APC
and T cells (38). In line with previous observations on
lovastatin and B cells (39), the antiproliferative effect of
atorvastatin examined in human antigen-specific T cells in
our work was not preceded by a reduced T cell activation
because calcium influx was unaffected. Furthermore, this
effect was not linked to the induction of apoptosis. Our
data indicate that the underlying mechanism for the inhi-
bition of T cell response in autoimmune neuroinflamma-
tion is the interference with cell cycle regulation repre-
sented by down-regulation of CDK4 and up-regulation of
p27kip1, which was reported previously as mechanism of
action of statins only in mesangial cells (40). Immunologi-
cal studies within clinical trials might finally clarify which
atorvastatin-mediated mechanism is important in case of a
beneficial effect in MS.
Via blocking HMG-CoA reductase and mevalonate syn-
thesis, statins prevent the synthesis of important isoprenoid
intermediates of the cholesterol biosynthetic pathway,
which are important for isoprenylation of certain cell-sig-
naling proteins (36). Thus, this posttranslational modifica-
tion of intracellular signaling molecules, such as small
GTP-binding proteins by isoprenylation (36), is involved
in the regulation of the cell cycle by statins. Small GTP-
binding proteins (e.g., Ras and Rho) require such post-
translational modification for membrane localization and
activity and are implicated in cell cycle regulation. Among
these proteins, Ras promotes cell cycle progression via acti-
vation of the mitogen-activated protein kinase pathway
(41), whereas Rho causes cellular proliferation possibly
through destabilizing p27kip1 protein (42). In fact, we could
Figure 4. Atorvastatin inhib-
its antigen-dependent prolifera-
tion of murine and human
TCLs. The murine CD4 PLP-
specific TCL Je1 (A) and the hu-
man BP-specific TCL MB8 (B)
were stimulated with () or
without () antigen presented
by irradiated autologous APC in
the absence or presence of differ-
ent concentrations of atorvastatin
(shaded bars) or vehicle alone
(open bars), and proliferation
was assessed. Striped bars corre-
spond to controls without ator-
vastin or vehicle.
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show that atorvastatin-induced up-regulation of p27kip1 is
blocked by l-mevalonate. Altogether, this pathway ex-
plains the down-regulation of CDK4 and up-regulation of
p27kip1 by atorvastatin.
Our data provide compelling evidence for the beneficial
role of statins in neuroinflammation. In addition to the re-
ported pleiotropic mechanisms exhibited by this group of
substances, here we unravel the inhibition of HMG-CoA
reductase as a responsible mechanism for the direct T cell–
targeted influence of atorvastatin on proliferation and effec-
tor cytokines of Th1 cells. Due to the therapeutic potential
of this pathway in EAE, the activity of statins might open
up a new avenue for MS treatment with an orally adminis-
tered drug.
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Figure 5. Pathways used by atorvastatin to interfere with T cell cycle. Hatched bars (A and B) correspond to controls without atorvastatin, vehicle, or
l-mevalonate. (A) The representative human BP-specific TCL MB7 was stimulated with () or without () antigen presented by irradiated autologous
APC. Atorvastatin (shaded bars) or vehicle (open bars) was added immediately (0 h) or at later stages after 24 or 48 h, respectively. (B) MB7 was stimu-
lated with () or without () anti-CD3/CD28 in the presence or absence of atorvastatin or vehicle, respectively. Gray bars indicate the addition of
l-mevalonate (200 M). (C) Accordingly, IFN- was measured in the supernatant. The cytokine levels, derived from cells treated with (gray bars) or
without (black bars) l-mevalonate, are given in relation to vehicle control (dotted line). (D) The representative MBP-specific TCL EG8 is demonstrated
as an example for the measurement of Ca2 influx by flow cytometry. Cells were incubated for 24 h in the absence (control) or presence of atorvastatin
and Ca2 influx was monitored by a Tg model of CRAC activation (Materials and Methods). Gd3, a Ca2 entry blocker, was used as a positive control.
(E) Expression of CDK4 was assessed 24 h after anti-CD3/CD28 stimulation of the representative MBP-specific TCL EG7 by immunoblotting. (F) MB7
was used to demonstrate the CDK inhibitor p27kip1 regulation by atorvastatin and mevalonate blockade. (G) Jurkat T cells were incubated with () or
without () 10 U/ml murine CD95 ligand as controls (hatched bars) or with the indicated concentrations of atorvastatin or vehicle, respectively. After
24 h, specific DNA fragmentation was measured by flow cytometry.
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Figure 1.  
Atorvastatin suppresses the clinical severity of EAE in a preventive and therapeutic manner. 
(A) For the preventive treatment paradigm, 200 μg atorvastatin (n = 12; shaded circles) or 
vehicle alone (n = 12; open circles) were injected subcutaneously daily from the day of 
immunization onward. Both the maximum disease scores and the mean clinical disease scores 
were significantly reduced in the atorvastatin group. (B) For the nonpreventive therapy, mice 
were randomized into two groups (n = 8 for both groups) after the establishment of disease at 
day 10 and subsequently treated. Significant differences were noted for the maximum disease 
scores, the relapse incidence, and the mean disease scores for the time of the relapse. (C) Mice 
were treated subcutaneously with 20 μg atorvastatin (n = 10 for atorvastatin group, n = 7 for 
vehicle group). (D) For oral therapy, mice were treated with 200 μg (n = 7 for both groups). 
For all trials, treatment periods are indicated by horizontal hatched bars. The treatment effect 
was statistically significant as outlined in the marked range for all presented EAE courses (*, 
P < 0.05, analysis of variance). 
 
 
 
 
 
 
 
 
  
 
Figure 2.  
Decreased inflammation in spinal cords of atorvastatin-treated mice. Representative histology 
of spinal cord longitudinal sections was obtained from the EAE course presented in Fig. 1 A. 
Inflammatory infiltration was visualized by hematoxylin and eosin staining. (A) Vehicle-
treated animals showed typical perivascular infiltrates (arrowheads) comprised of 
lymphocytes and macrophages. (B) In contrast, atorvastatin-treated animals showed a 
markedly reduced inflammatory reaction. Average number of inflammatory foci/ocular field ± 
SEM in spinal cords of atorvastatin- and vehicle-treated mice as detected in hematoxylin and 
eosin–stained sections (P < 0.01, Student's t test). 
 
 
 
  
Figure 3.  
Atorvastatin treatment in vivo suppresses the PLP-specific priming response. Three mice per 
group were treated with either atorvastatin (200 µg per mouse) or vehicle from day 1 after 
immunization with PLP as described in Materials and Methods. (A) Proliferation of 
splenocytes in response to PLP (at the indicated concentrations) was assessed in quadruplicate 
cultures and expressed as stimulation index (mean ± SEM; atorvastatin, shaded bars; vehicle, 
open bars). (B) Accordingly, IL-2 was determined in the supernatants. Whereas IL-12 (C) as 
well as IFN-γ (D) were found at lower concentrations in the atorvastatin-treated mice than in 
those vehicle-treated, levels of IL-4 (E) and IL-10 (F) were higher in supernatants from 
splenocytes after treatment with atorvastatin. Data are presented as mean ± SEM; differences 
between atorvastatin and vehicle treatment are significant (P < 0.05; Student's t test). 
 
 
  
Figure 4.  
Atorvastatin inhibits antigen-dependent proliferation of murine and human TCLs. The murine 
CD4+ PLP-specific TCL Je1 (A) and the human BP-specific TCL MB8 (B) were stimulated 
with (+) or without (−) antigen presented by irradiated autologous APC in the absence or 
presence of different concentrations of atorvastatin (shaded bars) or vehicle alone (open bars), 
and proliferation was assessed. Striped bars correspond to controls without atorvastin or 
vehicle. 
 
 
  
 
Figure 5.  
Pathways used by atorvastatin to interfere with T cell cycle. Hatched bars (A and B) 
correspond to controls without atorvastatin, vehicle, or l-mevalonate. (A) The representative 
human BP-specific TCL MB7 was stimulated with (+) or without (−) antigen presented by 
irradiated autologous APC. Atorvastatin (shaded bars) or vehicle (open bars) was added 
immediately (0 h) or at later stages after 24 or 48 h, respectively. (B) MB7 was stimulated 
with (+) or without (−) anti-CD3/CD28 in the presence or absence of atorvastatin or vehicle, 
respectively. Gray bars indicate the addition of l-mevalonate (200 μM). (C) Accordingly, 
IFN-γ was measured in the supernatant. The cytokine levels, derived from cells treated with 
(gray bars) or without (black bars) l-mevalonate, are given in relation to vehicle control 
(dotted line). (D) The representative MBP-specific TCL EG8 is demonstrated as an example 
for the measurement of Ca2+ influx by flow cytometry. Cells were incubated for 24 h in the 
absence (control) or presence of atorvastatin and Ca2+ influx was monitored by a Tg model of 
CRAC activation (Materials and Methods). Gd3+, a Ca2+ entry blocker, was used as a positive 
control. (E) Expression of CDK4 was assessed 24 h after anti-CD3/CD28 stimulation of the 
representative MBP-specific TCL EG7 by immunoblotting. (F) MB7 was used to demonstrate 
the CDK inhibitor p27kip1 regulation by atorvastatin and mevalonate blockade. (G) Jurkat T 
cells were incubated with (+) or without (−) 10 U/ml murine CD95 ligand as controls 
(hatched bars) or with the indicated concentrations of atorvastatin or vehicle, respectively. 
After 24 h, specific DNA fragmentation was measured by flow cytometry. 
 
